-
Cergentis FFPE-TLC
Study
EGAS50000000427
-
Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial
Study
EGAS50000000387
-
Genomic and clinical characterization of a familial GIST kindred intolerant to imatinib
Study
EGAS50000000372
-
Copy number variations and fragmentation features in cell-free DNA predict response in advanced non-small cell lung cancer patients under anti-PD-(L)1 therapy
Study
EGAS50000000441
-
A 3D genome atlas of breast cancer progression (BRCA3D)
Study
EGAS50000000444
-
Multiple Myeloma GWAS Meta-analysis
Study
EGAS50000000292
-
Multi-omic analysis of SDHB-related PCPG
Study
EGAS50000000346
-
Genome and transcriptome sequencing of cancer of unknown primary tumours
Study
EGAS50000000452
-
Circulating immune cell landscape in colorectal cancer patients
Study
EGAS50000000590
-
Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer (NABUCCO Cohorts 1 and 2)
Study
EGAS00001004521